Immunocytokines for Cancer Immunotherapy
Authors:
- Paul M. SondelPSPaul M. Sondel
- Steven D. GilliesSGSteven D. Gillies
- 1 January 2004
- book chapter
- Published by Springer Nature
- p. 341-358
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Melanoma immunotherapy by targeted IL-2 depends on CD4+ T-cell help mediated by CD40/CD40L interactionJournal of Clinical Investigation, 2000
- ImmunocytokinesPharmacology & Therapeutics, 1998
- A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastomaCancer, 1997
- T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.Journal of Experimental Medicine, 1996
- Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic EffectsStem Cells, 1996
- Targeting cancer with radiolabeled antibodiesImmunology Today, 1995
- Recent developments in immunotoxin therapyCurrent Opinion in Immunology, 1994
- Applications of monoclonal antibodies in clinical oncologyImmunology Today, 1994
- Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factorCancer Immunology, Immunotherapy, 1992
- Therapy of Colorectal Carcinoma with Monoclonal Antibodies (MAb17-1A) Alone and in Combination with Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF)Acta Oncologica, 1991